anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing Scutellariae Radix and Platycodi Radix is provided to ensure effect of reducing adipose, blood glucose, and blood lipid and to prevent or treat obesity and metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity and metabolic diseases contains Platycodi Radix and Scutellariae Radix extract as an active ingredient. A food composition for preventing or relieving obesity and metabolic diseases contains the Scutellariae Radix and Platycodi Radix. The extract is isolated using water or organic solvent. The organic solvent is methanol, ethanol, butanol, hexane, or ethylacetate. The metabolic diseases include diabetes, hyperlipidemia, hypertension, myocardial infarction, and cardiac failure.
A method and system assist a physician in performing an ophthalmic surgery. The method includes receiving a quasi-real time image of at least a first portion of the eye. The at least the first portion of the eye includes an operating field for the ophthalmic surgery. A recommended next region and a recommended next procedure are determined based on the quasi-real time image and a computational model of the eye. An expected next result for the recommended next procedure is calculated using the quasi-real time image and the computational model. The recommended next region, the recommended next procedure and the expected result are provided to the physician.
Laparoscopic Roux-en-Y gastric bypass (RYGB) is crucial for significant weight reduction and treating obesity-related issues. However, the impact of gastrojejunostomy (GJ) anastomosis diameter on weight loss remains unclear. We investigate this influence on post-RYGB weight loss outcomes. A systematic search was conducted. Six studies met the inclusion criteria, showing varied GJ diameters and follow-up durations (1-5 years). Smaller GJ diameters generally correlated with greater short-to-medium-term weight loss, with a threshold beyond which complications like stenosis increased. Studies had moderate-to-low bias risk, emphasizing the need for precise GJ area quantification post-operation. This review highlights a negative association between smaller GJ diameters and post-RYGB weight loss, advocating for standardized measurement techniques. Future research should explore intra-operative and AI-driven methods for optimizing GJ diameter determination.
FIELD: medicine, pharmaceutics. SUBSTANCE: suggested composition contains, wt. %: glutoxym, 0.45-0.55; theophylline, 0.22- 0.27; riboxine, 0.45-0.55; dimexide, 1.35-1.65; sodium chloride, 0.83-0.98; water for injections, the balance up to 30 g. Said mixture is placed into aerosol packing. Glutoxym is bis-(-gamma-L-glutamyl)-L-cistenyl-bis- glycine disodium salt. Glutovent aerosol provides the size of microparticle to range within 150-300 mcm. Aerosol is of immunomodulating, broncholytic and desensitizing activity. The method of prophylaxis and treatment of acute respiratory infections and chronic infectious- inflammatory diseases of the upper respiratory ways deals with inhalation introduction of aerosol pharmaceutical composition into nasopharynx and main bronchi area not rarely than once a day for a time necessary to achieve therapeutical effect. Glutovent aerosol is characterized of high therapeutical action, high bioavailability. EFFECT: more prolonged action of the preparation at no side effects. 6 cl, 4 ex, 2 tbl
Phosphoprotein enriched in astrocytes-15 (PEA-15) is a small protein created in neurons or astrocytic cells in brain. This protein which is a multi-functional protein can increase the cell survival rate thanks to its antiapoptotic and proapoptotic properties. Parkinson's disease is a neurodegenerative disease that dopamine neurons are reduced in substantia nigra in brain. The inventers found out that PEP-1-PEA-15 fusion protein can protect dopamine neurons from oxidation stress in SH-SY5Y neuroblastom cells and animals suffering from Parkinson's disease. It is confirmed that PEP-1-PEA-15 fusion protein can be transferred to SH-SY5Y cells and substantia nigra through western blot analysis. PEP-1-PEA-15 fusion protein prevents the active oxygen species production DNA tessellation induced to MPP+ and induces SH-SY5Y cell survival. Transmitted PEP-1-PEA-15 fusion protein improves the expression level of Bcl-2 protein but reduces the impression level of Bax protein. Also, PEP-1-PEA-15 fusion protein is transmitted to substantia nigra and prevents dopamine neuron cell death in substantia nigra. Therefore, PEP-1-PEA-15 fusion protein can prevent and treat Parkinson's disease.
* Therapy with dofetilide capsules must be initiated (and, if necessary, re-initiated) in a setting that provides continuous electrocardiographic (ECG) monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. Patients should continue to be monitored in this way for a minimum of three days. Additionally, patients should not be discharged within 12 hours of electrical or pharmacological conversion to normal sinus rhythm.
  * The dose of dofetilide capsules must be individualized according to calculated creatinine clearance and QTc. (QT interval should be used if the heart rate is <60 beats per minute. There are no data on use of dofetilide capsules when the heart rate is <50 beats per minute.)The usual recommended dose of dofetilide capsules is 500 mcg BID, as modified by the dosing algorithm described below. For consideration of a lower dose, see Special Considerationsbelow. 
  * Serum potassium should be maintained within the normal range before dofetilide treatment is initiated and should be maintained within the normal range while the patient remains on dofetilide capsules therapy. (See WARNINGS, Hypokalemia and Potassium-Depleting Diuretics). In clinical trials, potassium levels were generally maintained above 3.6 to 4.0 mEq/L. 
  * Patients with atrial fibrillation should be anticoagulated according to usual medical practice prior to electrical or pharmacological cardioversion. Anticoagulant therapy may be continued after cardioversion according to usual medical practice for the treatment of people with AF. Hypokalemia should be corrected before initiation of dofetilide therapy (see WARNINGS, Ventricular Arrhythmia). 
  * Patients to be discharged on dofetilide therapy from an inpatient setting as described above must have an adequate supply of dofetilide capsules, at the patient's individualized dose, to allow uninterrupted dosing until the patient can fill a dofetilide prescription.
Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
Individuals with dyslexia have been shown to have an increased risk for developing internalizing problems. Various studies have revealed the powerful role that culture plays in determining the type of anxiety and coping strategies adopted by various groups of individuals. However, compared to the vast number of studies conducted in individualistic cultures, knowledge on collectivistic cultures with respect to this issue is still limited. This study examined anxiety and coping strategies of children with and without dyslexia in Ethiopia, where the majority of its cultural dimensions could be regarded as collectivistic. A total of 126 children with (n = 63) and without (n = 63) dyslexia, aged 8-11 (41 boys and 22 girls, in each group; and age: M = 9.43 years; SD = 1.14 and M = 9.46; SD =1.11), participated. Dyslexia was assessed using an Amharic dyslexia assessment battery, while anxiety level and coping strategy were respectively measured using the Spence Children's Anxiety Scales (SCAS) and the Children's Coping Questionnaire (CCQ), both translated into Amharic. Results indicated that dyslexia was associated with higher levels of anxiety (especially generalized anxiety) and lower levels of support-seeking coping strategies. We discuss these results in the light of the cultural and institutional context in Ethiopia.
BACKGROUND: The global burden of chronic hepatitis B remains high and the best possible treatment remains long-term viral suppression expecting cure.
METHODS: Total 154 patients of chronic hepatitis B (48 HBeAg positive, e + ve) treated with oral entecavir (0.5 mg/1 mg per day) were recruited from June 2007 and followed prospectively until December 2022 for persistent HBV DNA negativity, HBeAg and HBsAg loss/seroconversion and other liver and drug-related events in real-life settings.
RESULTS: The mean duration of therapy was 6.78 (2-14) years with 1364 person-years of follow-up. All patients were HBV DNA negative by 15 months and remained so until the last follow-up. As many as 16.7% lost HBeAg after eight to 13 years of therapy, but not HBsAg. The mean fall in serum HBsAg level per year was 0.158 log IU/mL, being significantly higher in e + ve patients at baseline and until two years of therapy. The decline was significant until six years in e + ve patients compared to two years in e - ve ones. None had biochemical or virological breakthrough (except eight defaulters), flares or any untoward effects. The incidence of liver-related events, hepatocellular carcinoma and death was 10.4%, 1.9% and 14.3%, respectively, and 5.2% deaths were liver-related whose predictors were presence of cirrhosis (log rank 46.5, p > 0.001) and higher HBsAg level > 4 log IU/mL (log rank 18.15, p < 0.001) at baseline.
CONCLUSION: Long-term entecavir therapy provides additional benefits of continuous reduction of serum HBsAg levels beyond suppression of HBV DNA.
This prospective study was conducted at the Department for Visceral Surgery at the University Hospital of Lausanne Switzerland (CHUV) between February and December 2015 (NCT02356484). The study was approved by the Institutional Review Board (No. 367/15), and all patients provided written consent prior to surgery. Inclusion criteria were age \>18 years, and elective major abdominal surgery-defined as an operative procedure with anticipated duration ≥2 hours.17 Perioperative care closely adhered to recently published enhanced recovery guidelines (http://erassociety.org.loopiadns.com/guidelines/list-of-guidelines). Standardised fluid administration was followed by advanced haemodynamic monitoring to avoid intraoperative fluid overload. According to the clinical care pathway, intravenous fluid was typically discontinued the morning after surgery.

Biological markers Serum levels of albumin, CRP, PCT and lactate (LCT) were perioperatively measured in a fasting state, Following standardised institutional guidelines. Blood samples were drawn the day before surgery, the day of surgery (4-6 hours after the end of the operation) and on the first, second and third postoperative day. As Baseline values tend to show large variations especially for albumin,4 10 we considered that a dynamic value (difference between two time-points) might be more informative than a snapshot value. Several values based on preoperative and postoperative concentrations were thus calculated for each marker (ie, Δ Max: maximal difference between the preoperative and postoperative values; Δ POD 0: difference of concentration on POD -1 and POD 0; Δ POD 1: difference of concentration on POD-1 and POD 1).
The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
PROBLEM TO BE SOLVED: To obtain a skin external agent, capable of suppressing and improving the inflammation and the roughness of the skin caused by ultraviolet rays and having excellent feeling in use. SOLUTION: This skin external agent is obtained by compounding one or more kinds selected from an ultraviolet absorbent and an ultraviolet dispersant with an extract of Melissa officinalis of a plant belonging to the family Labiatae. The content of the extract of Melissa officinalis is 0.001-5wt.%, and that of an ultraviolet dispersant or an ultraviolet absorbent is 1-40wt.% when it is powder and 0.01-20wt.% when it is another form of ultraviolet absorbent. The extract of Melissa officinalis has an inhibiting effect on hyaluronidase activity and can exhibit synergistic effect on the improvement of skin symptom, antiinflammation, wound curing, the prevention of the skin from getting older, the improvement of rough skin, etc., by using the extract together with the ultraviolet absorbent and the ultraviolet dispersant.  The extract of Melissa officinalis is obtained by extracting flowers, stems, leaves, roots or seeds of Melissa officinalis in a raw or a dried state with a solvent (e.g. ethanol), and purifying and fractionating the crude extract.
An important complication of prolonged support of the left ventricle with an assist device when implanted in patients with heart failure is unloading-induced cardiac atrophy. Our recent study suggested that sex-linked differences in the development of atrophy induced by heterotopic heart transplantation (HTX) do exist, however, the role of the environmental conditions dependent on plasma concentrations of sex hormones remains elusive. We aimed to compare the course of HTX-induced cardiac atrophy in male and female rats after gonadectomy with substitution of steroid hormones of the opposite sex. In a separate series of experiments, we evaluated the course of unloading-induced cardiac atrophy in the female heart transplanted into a male recipient and vice versa. Cardiac atrophy was assessed as the ratio of the transplanted heart weight to native heart weight (HW), which was determined 14 days after HTX. In female rats, studied in both experimental variants, HTx resulted in significantly smaller decreases in whole HW when compared to those observed in male rats exposed to the same experimental conditions (-9 ± 1 and - 11 + 1 vs. -44 ± 2 and -42 ± 2 %, p?0.05 in both cases). The dynamic of changes in left and right ventricle was similar as in the whole HW. Our results show that the process of unloading-induced cardiac atrophy exhibits important sex-linked differences and that attenuation of this process in female rats cannot be simply ascribed to the protective effects of estradiol or to the absence of deleterious actions of testosterone. Keywords: Cardiac atrophy, Sex differences, Gonadectomy, Hormonal substitution, Heterotopic heart transplantation, Mechanical heart unloading.
The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP. '-04 po U? 0 po W, o 0 10 (D '0 ouileeq W4 *6uL~o
Fever is a frequent and important symptom in patients with rheumatological diseases and can be an expression of activity of the underlying rheumatological disease. There is great variability in the incidence of fever as a symptom of the disease between individual diseases. The growing understanding of the molecular signatures of the diseases can help to explain these discrepancies: A genetic overactivation of potently pyrogenic cytokines is the reason why fever is nearly always present in autoinflammatory syndromes. In contrast, fever is less common in polyarthritis and myositis and mostly limited to severe courses of disease. In the diagnostic work-up of fever, frequent differential diagnoses, such as infections, malignancies, side effects of drugs and hypersensitivity reactions should be considered. This article provides an overview of the physiology of the development of fever, describes the relevance of fever in individual rheumatological diseases and proposes a workflow for the clinical clarification of rheumatological patients who present with fever.
The present invention provides a hydrophobic cyclodextrin clathrate compound with a slow release effect, which is made by mixing a tert-butyl alcohol solution of hydrophobic cyclodextrin and a water phase solution containing hydrophilic medicine. The volume ratio of the tert-butyl solution to the water phase solution is 1 to 100:3. The mol mass ratio of the cyclodextrin to the hydrophilic medicine is 1 to 10:1. The present invention also discloses a method for preparing the clathrate compound. The method comprises the steps of: preparing the hydrophobic cyclodextrin tert-butyl alcohol solution and the water phase solution of the hydrophilic medicine; mixing both solutions into a single phase solution; and, drying, etc. The present invention also discloses an application of the cyclodextrin clathrate compound in pharmacy. Compared with the ordinary release preparations, the clathrate compound formed by the hydrophobic cyclodextrin and the water-soluble medicine is capable of reducing the solubility and digestion velocity of the water-soluble medicine and postponing the release of the medicine. The process is simple, convenient in operation, short in period, low in energy dissipation, and suitable for industrialized production, and has no residue of organic solvent.
BACKGROUND: Acute myeloid leukemia (AML) with myelodysplasia-related characteristics is a heterogeneous subset of AML that has been challenged throughout the history of myeloid malignancies classifications, considered to have similar outcomes as intermediate- or adverse-risk AML depending on the subgroup. However, little is known about the fate of these patients in refractory or relapsed situation (R/R) after first line therapy.
METHODS: A large series of R/R AML patients, recorded in the French DATAML registry, have received either intensive chemotherapy (ICT), azacitidine (AZA) as single agent, or best supportive care (BSC). A cohort of 183 patients (median age 63-year-old) with what was called at the time AML-MRC has been explored, and data are reported here.
RESULTS: Patient status was refractory for 93, while 90 had relapsed. Respectively, 88, 34, and 61 were included in the three treatment arms. The median OS of the whole cohort was 4.2 months (95%CI: 3.1-5.6) with a mean 1-year overall survival of 24% ± 3.2%. There was no significant survival difference between refractory and relapsed patients. The BSC group had overall a significantly worse outcome (p = 0.0001), and this remained true in both refractory (p = 0.01) and relapsed (p = 0.002) patients. Similar survivals were observed in both groups comparing ICT and AZA.
CONCLUSIONS: These data, reporting about an ill-explored population, indicate the poor prognosis of this condition where both ICT and AZA can be proposed. The latter, which was demonstrated here to be a feasible option, should be added to new targeted therapies.
Painful menstruation, also known as dysmenorrhea, is a common problem affecting a significant percentage of women. In the United States and Europe, nonsteroidal anti-inflammatory drugs (NSAIDs) and oral contraceptives are the most commonly prescribed treatments for this condition. However, in China, oral contraceptives are not commonly prescribed for unmarried women. Acu-injection, a procedure involving the injection of vitamin K into acupuncture points, has become standard treatment for dysmenorrhea at many Chinese health care facilities. This trial will assess the willingness of young Chinese women to participate in an acu-injection trial, explore the utility of pain measurements after injection, and determine the effectiveness of the injections. This study will also help in planning larger acu-injection clinical trials.

This study will last for five menstrual cycles. Participants will be randomly assigned to one of three groups. Group 1 participants will receive a vitamin K3 injection in an acupuncture point of both legs and a saline injection in the right buttock. Group 2 participants will receive a saline injection in an acupuncture point of both legs and a saline injection in the right buttock. Group 3 participants will receive a saline injection in a pseudo-acupuncture point of both legs and a vitamin K3 injection in the right buttock. Injections will be administered one time during the first 2 days of the first menstrual cycle for participants who are experiencing menstrual pain. Participants will record their level of menstrual pain before injection and at 2, 5, 30 and 60 minutes after the injections. Participants who do not respond to or are not satisfied with the acu-injection treatment will be offered either Chinese herbal medicine or NSAIDs within 1 hour of the injection. After the injection visit, participants will be asked to complete questionnaires about any menstrual pain or side effects they may be experiencing for five subsequent menstrual cycles.
For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
Contemporary walk test endpoints in IPF trials may under-represent patient functional gains with antifibrotic therapy, which may be more effectively captured with long-term activity monitoring. Traditional pulmonary rehabilitation centers create a barrier to patient exercise accessibility and compliance, which is eliminated in a mobile health (mHealth) exercise training approach. In this study, 30 patients with IPF will be randomized into one of two arms. The exercise arm will receive a 12-week home exercise intervention using an mHealth platform plus pre- and post-intervention monitoring (4 weeks each). The non-exercise arm will be monitored for the same study duration. The primary end point is change from baseline in daily physical activity as a number of weekly exercise minutes qualifying as moderate to vigorous physical activity (MVPA), METS\*minutes of exercise per week, and sedentary time minutes. Assessments will be performed primarily via in-person study visits at week 4 and week 16, as well as via daily recordings from mHealth monitoring devices.
A series of genes from Neisseria meningitidis are shown to encode gene products that are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application, including veterinary treatment. In particular the nucleotide sequence designated SEQID NO. 157 that encodes amino acid sequence designated SEQ ID NO. 158 are described.